Therapeutic outcomes of pemphigus in a referral service in Northern Brazil: a retrospective study of 32 patients
暂无分享,去创建一个
M. Xavier | C. Costa | Nathalia Gabay Pereira | Alyne Condurú dos Santos Cunha | Yandra Sherring Einecke | C. Pires | A. G. Moreira | F. N. Rodrigues
[1] G. Hans Filho,et al. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology* , 2019, Anais brasileiros de dermatologia.
[2] L. Bañez,et al. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis , 2018, PloS one.
[3] H. Shimizu,et al. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. , 2018, Journal of the American Academy of Dermatology.
[4] R. Pollmann,et al. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches , 2018, Clinical Reviews in Allergy & Immunology.
[5] L. Naldi,et al. Rituximab as first‐line adjuvant therapy for pemphigus: Retrospective analysis of long‐term outcomes at a single center , 2017, Journal of the American Academy of Dermatology.
[6] M. Mustapa,et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017 , 2017, The British journal of dermatology.
[7] M. Gdalevich,et al. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. , 2015, Journal of the American Academy of Dermatology.
[8] D. Zillikens,et al. Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] C. A. Pires,et al. Evaluation of cases of pemphigus vulgaris and pemphigus foliaceus from a reference service in Pará state, Brazil* , 2014, Anais brasileiros de dermatologia.
[10] E. Hodak,et al. Diagnosis and classification of pemphigus and bullous pemphigoid. , 2014, Autoimmunity reviews.
[11] H. Kim,et al. Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 Patients , 2011, Dermatology.
[12] D. Murrell,et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. , 2009, The Cochrane database of systematic reviews.
[13] H. Shimizu,et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.
[14] T. Hashimoto. Treatment strategies for pemphigus vulgaris in Japan , 2008 .
[15] C. Chams‐Davatchi,et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. , 2007, Journal of the American Academy of Dermatology.
[16] J. Roujeau,et al. A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.
[17] S. Fedele,et al. High-dose intravenous 'pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[18] N. Fernandes,et al. Treatment of pemphigus vulgaris and pemphigus foliaceus: experience with 71 patients over a 20 year period. , 2001, Revista do Instituto de Medicina Tropical de Sao Paulo.
[19] R. Wolf,et al. Early treatment of pemphigus does not improve the prognosis A review of 53 patients , 1995 .
[20] S. Tavakolpour,et al. Sixteen‐year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review , 2018, International immunopharmacology.
[21] M. Shahidi-Dadras,et al. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. , 2007, Archives of Iranian medicine.